Korean BNC Partner OncoGen Presents Dual-Target Triple-Negative Breast Cancer Research Results at International Oncology Conference

Korea BNC announced on the 4th that its partner anti-cancer venture company OncoGen (CEO An Joo-hoon) participated in the European Society for Medical Oncology Asia Congress (ESMO ASIA 2023) held in Singapore from the 1st and disclosed research results on a dual-target anti-cancer drug for triple-negative breast cancer.

This research has been jointly developed through strategic investment by Korea BNC in OncoGen. The two companies signed a joint research and development agreement for a first-in-class dual-target innovative anti-cancer drug and an exclusive domestic licensing agreement in February.

The pipeline introduced by OncoGen at this conference is a dual-target single oral anti-cancer drug under development. This drug simultaneously blocks calcium, which is overexpressed in cancer cells and essential for cancer cell growth, and inhibits the target protein STAT3 (Signal transducer and activator of transcription 3).

An OncoGen official stated, “Our dual-targeting drug has already demonstrated efficacy in various solid tumors such as lung cancer, pancreatic cancer, and triple-negative breast cancer,” adding, “In particular, in a triple-negative breast cancer animal model, it showed an outstanding anti-cancer effect of about 90-95%, leading to the presentation of results for clinical entry at ‘ESMO ASIA 2023.’” He further noted, “Starting with this presentation, we plan to continue broad international exchanges.”

A Korea BNC official said, “The two companies will continue to cooperate steadily and plan to conduct Phase 1 clinical trials in Australia in 2024,” adding, “We will strive to achieve meaningful new drug development outcomes such as global anti-cancer drug development and technology transfer.”